No profile data available.
Evolus, Inc. (EOLS) is a healthcare company in the skin treatment pharmaceuticals industry, based in Newport Beach, United States, with about 353 full-time employees.
It reported revenue of $266.27 million for fiscal year 2024, up 31.8% from fiscal year 2023, and net income of -$50.42 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $68.97 million, up 12.9% from a year before. Its market capitalization was $510.57 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
Evolus reported $266.27 million in revenue for fiscal year 2024, up 31.8% from $202.09 million in fiscal year 2023. In Q3 2025 revenue was $68.97 million.
$510.57 million as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Trevi Therapeutics, Inc. (TRVI), Avalo Therapeutics, Inc. (AVTX), Aclaris Therapeutics, Inc. (ACRS), Abeona Therapeutics Inc. (ABEO).